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REVIEWS
MODERN RADIOLOGICAL DIAGNOSIS  
OF HEPATOCELLULAR CARCINOMA
Ivaylo Vazharov 
Department of Gastroenterology, Naval Hospital of Varna,  
Military Medical Academy of Sofia
Final diagnosis in oncology is 
pathomorphological. However, the detection of 
hepatocellular carcinoma (HCC) is based on imaging 
methods and it is always a problem for the physicians. 
In the past, scintigraphy was the basic method for 
HC diagnosis. This does not represent a diagnostic 
method of choice anymore.
Usually, ultrasound examination (US) is the 
first and cheapest imaging instrumental method 
used in patients suspicious of presence of focal lesions 
of the liver. The main limitations of this method are 
the dependency on US specialist’s experience and the 
equipment used, the difficulty in diffuse liver disease 
and the low specificity (25). The percutaneous US 
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can’t be used as the only method of diagnosis of 
HCC, however, it is suitable for screening (24). The 
sensitivity and specificity of US regarding the focal 
hepatic lesions increase with the introduction of 
the contrast-enhanced US (CEUS) and the method 
gets comparable to the contrast-enhanced computer 
tomography (CT) and magnetic resonance imaging 
(MRI) (27). This places CEUS in the diagnostic 
algorithm for distinguishing the malignant from the 
benign lesions before the puncture techniques (21). 
In the end of the 70’s, fine needle biopsy (FNB) 
under US control was introduced in the clinical 
practice to differentiate the focal lesions in liver 
parenchyma. FNB is not recommended for most 
cases because it is connected with poor survival rates 
after hepatic resection (22).
Spiral CT with contrast enhancement is the 
fundamental examination for initial staging and 
observation of HCC (8). This is extremely important 
for the malignant lesions in hepatic cirrhosis. 
Nowadays CT with arterioportography and CT 
arteriography are the most sensitive methods for 
detection of malignant hepatic lesions (10). However, 
they are invasive and expensive and lead to highly 
frequent falsely positive results.
ABSTRACT
Hepatocellular carcinoma is the most common primary tumour of the liver. It is characterized by a quick 
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MRI is the basic method of additional imaging 
evaluation of the liver (29).  In view of its high cost, 
MRI examination is performed when either the 
attending physician decides that it is necessary, or the 
patient is allergic to iodine.
Founding whatever lesion depends on its size 
and ‘the difference in the contrast’ between the lesion 
and the surrounding hepatic parenchyma (8). For 
that reason, contrast materials are obligatorily used 
providing greater difference (‘contrast’) between 
the intact and pathological tissue. HCC radiological 
characteristic consists in the arterial vascularity and 
venous wash off (14). This means that during the 
examination (CT, MRI or CEUS), the tumour has 
a brighter signal then the liver in the arterial phase, 
and in the venous or late phase of the examination 
the lesion is less contrasted then the surrounding 
hepatic parenchyma (23).
Positron-emission tomography (PET) is a very 
precise method in determining the presence or 
absence of hepatic metastases. However, its role in 
HCC is limited because its diagnostic sensitivity is 
50-60% only (28).
The invasive methods of examination enhance 
the diagnostic opportunities. The image of the left 
lobe of the liver with a high resolution can be obtained 
with endoscopic US and FNB can be performed under 
its control (1). Laparoscopy and laparoscopic US are 
other invasive methods to diagnose and determine 
the optimal strategy of treatment of HCC (13).
Ultimately, the choice of imaging modality to 
detect, evaluate and follow-up the tumours of the 
liver must be based not only on the patient and its 
clinical conditions, but also on the experience in the 
imaging modalities within each medical institution.
Although there are many imaging methods, 
based on the preferences and experience of the 
institutions, CT is the most common imaging 
method of graphic examination of the liver in the 
diagnostics of patients with suspicious HCC (5).
Regardless of the attainments of the 
technologies, the sensitivity of the preoperative 
imaging modalities remains 60-80% (20). The small 
lesions in the liver may be early HCC, regenerative 
and dysplastic nodules. The early lesions must be 
operated with a high probability of recovery (19). 
They are most difficult to diagnose. In contrast to 
the classic HCC, early HCC is hypovascular due to a 
reduced portal venous supply of the lesion as well as 
because the arterial vascularization is not completely 
developed. There is a radiological pathognomonic 
sign of HCC, i. e., arterial vascularity and venous 
wash out (23).
Tumour markers don’t have any high sensitivity 
nd specificity as well as they present with less organ 
specificity for diagnosing primary tumours or 
metastatic disease of the liver. Hopes are high that 
genome and proteome tumour markers will gain 
ground as early markers of malignancy.
Alpha-fetoprotein is widely used in following-
up the primary HC, especially in patients with 
cirrhosis (16). Other perspective markers are des-
gamma-carboxy-prothrombine (DCP) and AFP-
L3%, the agglutinin reactive fraction of AFP (7,17). 
The role of AFP markers is challenged in the era of 
the sensitive imaging modalities (9), moreover, it 
is not included in the guidelines of observation of 
primary liver carcinoma of the American Association 
of Studying the Hepatic Diseases (18). The sensitivity 
and specificity of the AFP assay at entry at the cut 
off level of 20 ng/dL are 41% and 82%, respectively, 
with a positive predictive value of 46% and negative 
predictive value of 85% (3). AFP values >400 ng/mL 
are indicative of HCC. Thirty-percent of the patients 
with HCC <2 cm present with normal AFP and levels 
20-250 ng/dL are common in regenerative nodules or 
viral cirrhosis. AFP elevation with time is actually of 
diagnostic value for HCC (4).
Hepatic resection surgery is still the golden 
standard in the treatment of the primary liver 
tumours with results unattainable for the other 
therapeutic methods - a five-year survival rate over 
50% for HCC (15). Local treatment is the alternative 
of the operative treatment consisting in the so-
called percutaneous methods such as cryoablation, 
radiofrequent ablation, microwave ablation, laser 
ablation, injecting of ethanol which are recommended 
in small tumours sized at an average up to 5 cm, 
and better, in smaller ones - up to 3 cm when there 
are contraindications for operative treatment (2). 
The experience with chemotherapy for HCC is 
disappointing, too, because of the low response and 
high toxicity. Sorafenib, an oral multikinase with 
activity toward tumour cellular proliferation and 
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angiogenesis, has a moderate effect in advanced 
primary HC without any significant toxicity (12).
During operation, the surgeons routinely 
examine the liver by inspection and palpation. So, 
small and deeply localized lesions can be easily 
missed. The solid and uneven surface of the liver 
makes detecting by palpation the small HCC nodules 
quite difficult (30). Many of these impalpable lesions 
provide greater chances for the patient (11).
This deficiency must be compensated and 
thus the intraoperative ultrasound (IOUS) has 
been introduced in the clinical practice. In a study 
performed in the Naval Hospital of Varna, Military 
Medical Academy of Sofia, in 12 operated HCC 
patients, 11 men and one woman at a mean age of 
58 years, during the period from 2007 to 2011, IOUS 
establishes additional malignant lesions, not detected 
by US and CT, in four (33,33%) and five  (41,67%) 
patients, respectively. This is due to detecting the 
small lesions (<20 mm), where IOUS finds out 12 
small lesions of a total of 25 ones, while US and CT 
detect one lesion each. The additional information 
from IOUS led to change of the operative plan in four 
patients (33,33% of the cases) (26).
In conclusion, we should note that the precise 
preoperative imaging diagnostics with defining the 
number, size and form of HCC, its localization and 
the interrelation with the intra- and extra-hepatic 
structures such as vascular and biliary vessels and 
neighbouring organs is of crucial significance for the 
effective operative removal of any detectable hepatic 
tumours. Unfortunately, notwithstanding the 
technologic progress in imaging diagnostic methods, 
the abovementioned literature data unambiguously 
indicate that at this stage, the non-operative staging 
of the liver tumours is not precise enough for the 
planning of effective treatment yet.
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